29947-24-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4,5-dimethyl-1,3-thiazole is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be incorporated into the development of new medications, potentially contributing to the treatment of a range of medical conditions.
Used in Organic Synthesis:
In the field of organic chemistry, 2-Bromo-4,5-dimethyl-1,3-thiazole serves as a valuable intermediate for the preparation of other complex organic compounds. Its reactivity and structural features make it a useful building block in the synthesis of a variety of chemical products, including specialty chemicals and advanced materials.

Upstream product

• 3581-91-7 4,5-Dimethylthiazole 
• 7170-76-5 2-amino-4,5-dimethylthiazole hydrobromide 

Downstream Products

• 5351-51-9 4,5-dimethylthiazole-2-thiol 
• 69389-13-5 1-(4,5-dimethyl-thiazol-2-yl)-piperazine 
• 99839-16-4 (4,5-dimethyl-1,3-thiazol-2-yl)methanol 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS

The present teachings relate to compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, R4, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I and methods of inhibiting matrix metalloproteinases, in particular, MMP-12, that may be involved in pathological disorders found in mammals, including a human.

CARBACEPHEM β-LACTAM ANTIBIOTICS

Carbacephem -lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar1, Ar2, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

CARBACEPHEM β-LACTAM ANTIBIOTICS

Carbacephem β-lactam antibiotics having the following chemical structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

Selective Bromination of 4,5-Dimethylthiazole with N-Bromosuccinimide

Radical bromination of 4,5-dimethylthiazole (1) was carried out using different stoichiometries of N-bromosuccinimide in the presence of 2,2'-azobisisobutyronitrile.Mono-, tri- and tetrabromo compounds 2, 5, and 6 were obtained in good yields with regioselectivity while the dibromo derivatives 3 and 4 were formed without any selectivity.Substitution at the thiazole ring occurred in the presence of silica gel or in the perfluoro ether FC-77 (C8F16O), affording the 2-bromothiazole 7.The order of reactivity observed was 5-Me > 4-Me > C-2.Structural assignment of compounds 2-7 was made by chemical correlations and NMR spectroscopy. - Keywords: Heterocycles; NBS bromination; Selective bromination; Polybrominated thiazole; Structure elucidation